Serum levels of novel anti-inflammatory cytokine Interleukin-38 in diabetes patients infected with latent tuberculosis (DM-LTB-3)

J Diabetes Complications. 2022 Mar;36(3):108133. doi: 10.1016/j.jdiacomp.2022.108133. Epub 2022 Jan 22.

Abstract

IL-38 is a recently discovered, novel anti-inflammatory cytokine, which belongs to the IL-1β family. The role played by this cytokine in diabetes-tuberculosis nexus is not known. Serum levels of IL-38, TNF-α, IL-6, and IL-1β in Normal Glucose Tolerance (NGT) and chronic Diabetes (DM) subjects, both with and without latent tuberculosis (LTB) (n = 256) were quantified by ELISA. While, serum levels of IL-38 were significantly reduced, the levels of TNF-α, IL-6, and IL-1β were not altered, in LTB infected diabetes patients. While no significant secretion of IL-38 was detected in the quantiferon supernatant, secretion of TNF-α, IL-6, and IL-1β was significantly reduced in LTB infected diabetes patients. The decreased systemic levels of IL-38 and reduced in vitro secretion of other pro-inflammatory cytokines might represent a crucial pathway associated with diabetes-tuberculosis nexus.

Keywords: Diabetes; IL-1β; IL-38; IL-6; Impaired immunity; Inflammation; Latent tuberculosis; Quantiferon; TNF-α.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cytokines* / blood
  • Diabetes Complications / immunology
  • Diabetes Mellitus* / blood
  • Diabetes Mellitus* / immunology
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Interleukins* / blood
  • Interleukins* / immunology
  • Latent Tuberculosis* / blood
  • Latent Tuberculosis* / complications
  • Latent Tuberculosis* / immunology
  • Tumor Necrosis Factor-alpha

Substances

  • Cytokines
  • IL-38 protein, human
  • Interleukins
  • Tumor Necrosis Factor-alpha